ClinicalTrials.gg
TerminatedNCT07431398Updated Jun 18, 2026

Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

A Phase 1 interventional study of Pociredir in Sickle Cell Disease, sponsored by Fulcrum Therapeutics. Terminated at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Fulcrum Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
422nd of 559
13 · median 31
Started
2025
with 33 others
Phase 1
98 of 733
13 open now
Registered
715th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 422nd largest by enrollment of the 559 interventional ones that give a count, is one of 34 that started in 2025, is one of 98 in phase 1, and was the 715th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).

Read the detailed description

The study is designed to assess the pharmacokinetics of the tablet formulation of pociredir under fasted conditions in up to approximately 12 study participants with SCD (Fasted Cohort). An additional cohort of up to approximately 12 study participants with SCD may be enrolled to evaluate the potential effect of food on the PK of the tablet formulation (Fed Cohort). The fasted cohort will be conducted first.

The study will include screening period: Day -28 to Day -2; In-patient confinement period: Days -1 to 3; check-in on day -1; single dose of pociredir on day 1; discharge on Day 3; outpatient visit: Day 4; end of study (EOS) visit: Days 8-11

Eligible participants who meet all inclusion and none of the exclusion criteria will be admitted to the clinical site on Day -1, the day before dosing. Participants may be discharged on Day 3 following completion of 48-hour PK sampling or may remain in-clinic through Day 4 if needed. Fasted Cohort: Participants will fast for at least 10 hours prior to dosing and remain fasted for 4 hours post-dose. Water intake will be restricted for 1 hour before and after administration of the investigational medicinal product (IMP). Fed Cohort (if conducted): Participants will fast for at least 10 hours prior to breakfast and will receive a standard high-fat breakfast starting 30 minutes before dosing.

Pharmacokinetic samples will be collected up to 72 hours post-dose. Participants are required to remain in-clinic for the first 48 hours post-dose and may return to the site for subsequent Outpatient and EOS visits.

03

Conditions studied

  • Sickle Cell Disease

Keywords

  • Sickle Cell Disease
  • Hemoglobin subunit beta
  • fetal hemoglobin
  • Pharmacokinetics
  • Pociredir
  • FTX-6058
  • Tablet Pharmacokinetics Study
  • Anemia, Sickle Cell
  • Hematologic diseases
  • Small Molecule
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented SCD at the time of screening, as confirmed through review of medical records or high-performance liquid chromatography (HPLC)/electrophoresis.
  • Participant, who if female and of , agrees to use 2 effective methods of , one which must be highly effective, or practice abstinence starting at the time of the ICF signing to 90 days after the last dose of study drug, and, who if male, agrees to use condoms or practice abstinence from the time of ICF signing to 90 days after the last dose of study drug.
  • Total ≥ 5.5 grams/deciliter (g/dL) and ≤ 12 g/dL (males) or ≤ 10.6 g/dL (females) at screening
  • Participant must meet all of the following laboratory values at screening:

    1. ≥ 1.5 × 10\^9/L (cells/liter)
    2. ≥ 80 × 10\^9/L
    3. Absolute reticulocyte count > 100 × 10\^9/L
  • Participants who meet all other inclusion and exclusion criteria for this study, and per Investigator's recommendation may continue crizanlizumab, and/or L-glutamine, must be on a stable dose for at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Participant has had any of the following in the 14 days prior to dosing: major surgery, serious illness, infection ( bacterial, fungal, parasitic or viral infection which requires therapy), fever not resolved within 3 days and requiring treatment, or sickle cell complication requiring care from a medical provider in a hospital or emergency care setting.
  • Participant has a serious medical condition other than SCD that, in the opinion of the Investigator, would preclude them from participating in the study, or which is unresolved or requiring ongoing treatment.
  • Elective surgery planned for the time period of the study.
  • Use of any medications that induce or inhibit cytochrome P450 (CYP) 3A4, inhibit P-glycoprotein, breast cancer resistance protein, or multidrug and toxin extrusion protein 2-K, or are substrates of CYP2B6 within 14 days prior to first dose of study drug or anticipated need for any of these medications during the study.
  • Participation in any other study with an agent within the past 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug.
  • For Fed Cohort Only: Participant has special dietary restrictions or inability to consume standard meals as required in the study.

Note: Other protocol specified criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Fasted Cohort

    Pociredir single dose tablet formulation under fasted conditions.

    Drug: Pociredir

  • Experimental
    Fed Cohort

    Pociredir single dose tablet formulation under fed conditions (after a high-fat breakfast).

    Drug: Pociredir

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma concentration of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  2. Maximum plasma concentration (Cmax) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  3. Area under the plasma concentration-time curve from time 0 to 24 hours (AUC(0-24)) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  4. Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-tlast)) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  5. Area under the plasma concentration-time curve from time 0, extrapolated to infinity (AUC(0-inf)), of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  6. Time to maximum plasma concentration (Tmax) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  7. Terminal disposition rate constant (λz) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  8. Terminal half-life (t1/2) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  9. Apparent volume of distribution during the terminal phase (Vz/F) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

  10. Apparent clearance (CL/F) of pociredir under fasted and fed conditions

    Time frame: Day 1 through Day 4

Secondary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs) under fasted and fed conditions

    Time frame: Up to Day 11

  2. Number of participants with clinically significant changes in safety assessments under fasted and fed conditions

    Time frame: Up to Day 11

  3. Number of participants with clinically significant findings in clinical laboratory evaluations, vital signs, electrocardiogram (ECGs) and physical examination

    Time frame: Up to Day 11

  4. Plasma concentration of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  5. Cmax of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  6. AUC(0-24) of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  7. AUC(0-tlast) of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  8. AUC(0-inf), under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  9. Tmax of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  10. λz of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  11. t1/2 of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  12. Vz/F of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

  13. CL/F of pociredir under fasted and fed conditions compared to healthy participants

    Time frame: Day 1 through Day 4

07

Study locations

6 sites
  • Advanced Pharma - Miami
    Miami, Florida 33147, United States
  • Omega Research Group
    Orlando, Florida 32808, United States
  • Sonar Clinical Research
    Riverdale, Georgia 30274, United States
  • Neuro-Behavioral Clinical Research
    North Canton, Ohio 44720, United States
  • University of Texas Health Science Center Houston
    Houston, Texas 77030, United States
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Jun 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 24, 2026
StartActual
Dec 13, 2025
Primary completionActual
Jun 1, 2026
CompletionActual
Jun 1, 2026
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431398
Lead sponsor
Fulcrum Therapeutics
Responsible party
Sponsor
First posted
Feb 24, 2026
Start date
Dec 13, 2025
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026
Last update
Jun 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pociredir

Start the discussion